June 2011
Volume 52, Issue 7
Letters to the Editor  |   June 2011
Incorrect Citation
Author Affiliations & Notes
  • David O. Bates
    Microvascular Research Laboratories, School of Veterinary Sciences, Bristol, United Kingdom.
Investigative Ophthalmology & Visual Science June 2011, Vol.52, 4368. doi:https://doi.org/10.1167/iovs.11-7310
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      David O. Bates; Incorrect Citation. Invest. Ophthalmol. Vis. Sci. 2011;52(7):4368. https://doi.org/10.1167/iovs.11-7310.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements
In their letter in the December 2010 issue, “Author Response: Bevacizumab Suppression of Establishment of Micrometastases in Experimental Ocular Melanoma” Yang et al. 1 state that “bevacizumab has been used in mouse models of choroidal neovascularization” and quote Hua et al., 2 for which I am the corresponding author. This is an incorrect and misleading reference. We certainly did not show that bevacizumab affected mouse models of choroidal neovascularization, only that it inhibited human VEGF165-mediated migration of endothelial cells at the same dose-response as VEGF165b. 
Yang H Jager MJ Grossniklaus HE . Author response: bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma. Invest Ophthalmol Vis Sci. 2010;51:6906–6907. [CrossRef] [PubMed]
Hua J Spee C Kase S . Recombinant human VEGF165b inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2010;51:4282–4288. [CrossRef] [PubMed]

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.